| Literature DB >> 27491412 |
Stefano Aliberti1, Eleonora Tobaldini2, Fabio Giuliani3, Vanessa Nunziata2, Giovanni Casazza4, Giulia Suigo5, Alice D'Adda3, Giulia Bonaiti5, Andrea Roveda2, Andreia Queiroz2,6, Valter Monzani7, Alberto Pesci5, Francesco Blasi3, Nicola Montano2.
Abstract
BACKGROUND: Alterations of cardiac autonomic control (CAC) are associated with poor outcomes in patients with infectious and non-infectious diseases. No evaluation of CAC in patients with community-acquired pneumonia (CAP) has been performed so far. The aim of the study was to assess CAC in patients with CAP and evaluate the impact of its alterations on disease severity and clinical outcomes in a multicenter, prospective, observational study.Entities:
Keywords: Cardiac autonomic control; Heart rate variability; Pneumonia; Spectral analysis; Symbolic analysis; Sympathetic
Mesh:
Year: 2016 PMID: 27491412 PMCID: PMC4973093 DOI: 10.1186/s12931-016-0414-8
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Baseline demographics, comorbidities, disease severity, clinical and laboratory findings on admission, microbiology, and antibiotic therapy of the study population
| Study population | |
|---|---|
| Demographics, | |
| Male | 43 (57) |
| Age, median (IQR) years | 75 (59–84) |
| Body mass index, median (IQR) | 24 (20–27) |
| Healthcare-associated pneumonia | 5 (7) |
| Comorbidities, | |
| Active neoplastic disease | 12 (16) |
| Chronic obstructive pulmonary disease | 18 (24) |
| Diabetes mellitus | 11 (15) |
| Cerebrovascular accident | 9 (12) |
| Liver disease | 5 (7) |
| Neurological diseases | 11 (15) |
| Renal disease | 8 (11) |
| Chronic renal failure | 6 (8) |
| Family history of coronary artery disease | 16 (21) |
| Essential arterial hypertension | 36 (48) |
| Congestive heart failure | 7 (9) |
| Active coronary artery disease | 12 (16) |
| Prior acute myocardial infarction | 10 (13) |
| Atrial fibrillation | 2 (3) |
| Hyperlipidemia | 14 (19) |
| Medications before admission, | |
| Aspirin | 17 (23) |
| Beta-blockers | 13 (17) |
| Angiotensin-converting-enzyme inhibitors | 14 (19) |
| Antiplatelets | 8 (11) |
| Statins | 12 (16) |
| Severity on admission, | |
| Mental status change | 4 (5) |
| PSI Risk Class IV and V | 54 (72) |
| PSI Risk Class V | 21 (28) |
| Acute respiratory failure | 39 (52) |
| Severe sepsis | 14 (19) |
| Clinical and laboratory data on admission, median (IQR) | |
| Heart rate, bpm | 80 (71–92) |
| Respiratory rate, bpm | 20 (18–25) |
| Systolic blood pressure, mmHg | 128 (115–146) |
| Diastolic blood pressure, mmHg | 70 (60–80) |
| White blood cells, cell/L−1 | 11,840 (9180–15,900) |
| Hemoglobin, g/dL | 12.6 (11–14.2) |
| Hematocrit, % | 37 (33–41) |
| Albumin, g/dL | 3.3 (3.1–3.8) |
| Platelets, cell/L−1 | 196,000 (161,000–289,000) |
| Lactate dehydrogenase, mg/dL | 378 (318–444) |
| Blood urea nitrogen, mg/dL | 40 (27–49) |
| Creatinine, mg/dL | 1 (0.8–1.3) |
| Sodium, mEq/L | 136 (133–139) |
| Potassium, mEq/L | 4 (3.7–4.4) |
| Glucose, mg/dL | 119 (106–146) |
| C-reactive protein, mg/L | 12.9 (6.25–28.8) |
| pH | 7.46 (7.44–7.48) |
| Microbiology, | |
| Isolated pathogen | 13 (17) |
|
| 8 (11) |
|
| 2 (3) |
|
| 2 (3) |
|
| 1 (1) |
| Empiric antibiotic treatment, | |
| Ceftriaxone | 36 (48) |
| Azithromycin | 38 (51) |
| Levofloxacin | 32 (43) |
| Ceftazidime | 8 (11) |
| Piperacillin/tazobactam | 9 (12) |
| Others | 23 (30) |
n. number, IQR 25–75 interquartile range, PSI pneumonia severity index
Autonomic parameters evaluated by both spectral and symbolic analysis in patients with community-acquired pneumonia (CAP) and controls
| CAP patients | Controls |
| |
|---|---|---|---|
| Parameter | |||
| Heart rate, median (IQR) bpm | 80 (71–92) | 68 (60–73) | 0.006 |
| Spectral analysis | |||
| Total power, median (IQR) ms2 | 159 (79–368) | 522 (335–1760) | <0.001 |
| VLF, median (IQR) ms2 | 49 (0–121) | 262 (99–983) | <0.001 |
| LFnu, median (IQR) | 32 (11–63) | 56 (37–75) | 0.008 |
| HFnu, median (IQR) | 42 (13–59) | 41 (22–55) | 0.935 |
| LF/HF, median (IQR) | 0.92 (0.23–2.6) | 1.3 (0.73–3.1) | 0.120 |
| HF Hz, median (IQR) | 0.31 (0.27–0.37) | 0.29 (0.26–0.33) | 0.096 |
| Symbolic analysis | |||
| 0V, median (IQR) % | 26 (13–38) | 30 (12–46) | 0.451 |
| 1V, median (IQR) % | 39 (33–47) | 44 (38–49) | 0.077 |
| 2LV, median (IQR) % | 4.4 (2.2–8.5) | 6.0 (3.5–12) | 0.164 |
| 2UV, median (IQR) % | 24 (12–41) | 17 (12–24) | 0.020 |
n. number, IQR 25–75 interquartile range, bpm beats per minute, ms milliseconds2, VLF very low frequency, LF low frequency, HF high frequency, nu normalized units, Hz Hertz
Fig. 1Evaluation of cardiac autonomic control in the study population, according to presence of severe community-acquired pneumonia (CAP)
Spectral and symbolic analysis among patients who reached clinical stability within 7 days vs. after 7 days from hospital admission
| TCS ≤7 days | TCS >7 days |
|
| |
|---|---|---|---|---|
| Parameters, | ||||
| Heart rate, median (IQR) bpm | 79 (70–89) | 81 (72–96) | 0.305 | 0.712 |
| Spectral analysis | ||||
| Total power, median (IQR) ms2 | 233 (105–433) | 94 (59–214) | 0.002 | 0.001 |
| VLF, median (IQR) ms2 | 87 (11–211) | 20 (0–66) | 0.001 | 0.003 |
| LFnu, median (IQR) | 32 (15–63) | 30 (4.3–68) | 0.611 | 0.823 |
| HFnu, median (IQR) | 43 (14–57) | 36 (12–63) | 0.795 | 0.823 |
| LF/HF, median (IQR) | 0.97 (0.25–2.4) | 0.78 (0.06–6.9) | 0.497 | 0.618 |
| HF Hz, median (IQR) | 0.30 (0.27–0.34) | 0.34 (0.29–0.42) | 0.041 | 0.106 |
| Symbolic analysis | ||||
| 0V, median (IQR) % | 28 (16–48) | 18 (10–30) | 0.026 | 0.059 |
| 1V, median (IQR) % | 41 (34–46) | 37 (31–49) | 0.732 | 0.674 |
| 2LV, median (IQR) % | 3.7 (1.7–6.7) | 6.7 (3.6–11.7) | 0.041 | 0.149 |
| 2UV, median (IQR) % | 20 (12–35) | 32 (18–45) | 0.017 | 0.092 |
* after adjustment for the presence vs. absence of severe CAP on hospital admission
n. number, IQR 25–75 interquartile range, TCS time to clinical stability, bpm beats per minute, ms milliseconds2, VLF very low frequency, LF low frequency, HF high frequency, nu normalized units, Hz Hertz